Markers for the diagnosis of large vessel occlusion
OwnerJoan Montaner Villalongainventor
Life of this patent
Estimating the term…
Abstract
A method for diagnosing large vessel occlusion in a subject that is suffering from an ischemic stroke episode, the method including determining the level of certain proteins in an isolated sample of a subject. A method for differentiating ischemic stroke from any other condition selected from haemorrhagic stroke, transient ischemic attack and a stroke mimicking condition. Simplified kits including reagents to carry out the methods are also disclosed.
Claims23
1-24. (canceled)
A method for treating large vessel occlusion (LVO) in a subject, said method comprising:
- a) obtaining an isolated sample from the subject;
- b) determining the level of a fatty acid binding protein (FABP) in the isolated sample, and comparing said level of FABP with a reference value or range;
- c) diagnosing the subject with LVO:
- when the reference value or range is of a subject suffering from LVO and the level of FABP in the isolated sample is equal or within said value or range;
- or
- when the reference value is a cut-off value discriminating between LVO from any other condition selected from one or more of a non-LVO ischemic stroke, an haemorrhagic stroke, a mimic, and a health subject, and level of FABP in the isolated sample is higher than the cut-off;
- or
- when the reference value is of a subject not suffering from LVO, and the level of FABP in the isolated sample is higher than the reference value;
- and
- d) treating the subject diagnosed with LVO with reperfusion therapy.
A kit comprising reagent means for simultaneously detecting the levels of a FABP, and of one or more of a natriuretic peptide, DDi, and GFAP.
A method for the treatment of LVO in a subject, said method comprising:
- a) obtaining an isolated sample from the subject;
- b) determining the level of a FABP in the isolated sample, and comparing said level of FABP with a cut-off value stratifying the patients according to either a dependency degree and/or a mortality rate:
- c) determining that the subject (i) has a prognosis defined by a dependency degree greater than 2 according to modified ranking score (mRS) determined within 1-5 months after stroke onset, and/or (ii) has a prognosis defined by a three-month after onset mortality rate comprised from 25%-35%, when the level of the FABP is higher than the cut-off value;
- and
- d) subjecting the subject with a prognosis defined by (i) a dependency degree greater than 2 according to modified ranking score (mRS) determined within 1-5 months after stroke onset, and/or (ii) a three-month after onset mortality rate comprised from 25%-35%, to reperfusion therapy and/or to a therapy with neuroprotective drugs.
Dependencies are inferred from the claim text.